Press Release

Global COVID Lab Meeting Will Bring Together the Worldwide Scientific Community to Accelerate Development of Vaccines and Immunotherapies

Apr 30, 2020

New York City (April 23, 2020). The Global COVID Lab Meeting will connect the worldwide scientific community working to develop vaccines and immunotherapies to end the COVID-19 pandemic. The Human Vaccines Project is starting this bi-weekly webinar to feature leading scientists from across the globe presenting their latest data, with ample time allowed for questions and discussion.

“The engines of science are the weekly or bi-weekly lab meetings held across the globe by individual laboratory directors, enabling faculty, post-docs and graduate students to present their latest findings and catalyze new ideas,” says Wayne C. Koff, president and CEO of the Human Vaccines Project. “The urgency of the pandemic, coupled with technological advances of distance learning, now enables us to bring the global scientific community together to accelerate the development of vaccines and immunotherapies for prevention and control of COVID-19. The Global COVID Lab Meeting will provide researchers with a neutral forum to share their findings and innovative ideas with scientists from across the world on a regular basis, thereby increasing the probability for identifying solutions towards ending the COVID-19 pandemic.”


“The urgency of the pandemic, coupled with technological advances of distance learning, now enables us to bring the global scientific community together to accelerate the development of vaccines and immunotherapies for prevention and control of COVID-19.”

WAYNE C. KOFF
President & CEO Human Vaccines Project

The webinar will be held every first and third Thursday of the month at 10 am EST. The first session is on May 7th. Dr. James E. Crowe Jr., Director of the Vanderbilt Vaccine Center, will talk about his studies on identification and development of human monoclonal antibodies for SARS-CoV-2 – a treatment that could provide immediate immunity to first responders. Dr. Crowe’s lab is one of the leading groups globally working on antibody identification and is targeting starting clinical studies early this summer for SARS-CoV-2 therapeutics. You can register for the webinar here.

The Global COVID Lab Meeting is part of the Human Vaccines Project’s recently established COVID Vaccine Initiative (CVI). The CVI aims to ensure the development of safe, effective, and accessible vaccines for those most vulnerable to COVID-19: aging populations and those living in low- and middle-income countries. It leverages HVP’s global clinical research consortium, including newly established collaborations with the Harvard T.H. Chan School of Public Health focused on deciphering effective immunity in aging populations; FHI 360, a global nonprofit research and human development organization with extensive experience working in low and middle-income countries; and the University of Minnesota’s Center for Infectious Disease Research and Policy, a global leader in addressing public health preparedness and emerging infectious disease response.